SEC Comment Letter for Arcutis Biotherapeutics, (ARQT) — Dec 2, 2025
Arcutis Biotherapeutics, Inc.
Date: Dec. 2, 2025 · CIK: 0001787306 · Accession: 0000000000-25-011158
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39186
Letter
December 2, 2025 Latha Vairavan Chief Financial Officer Arcutis Biotherapeutics, Inc. 3027 Townsgate Road Suite 300 Westlake Village, California 91361 Re:Arcutis Biotherapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed February 25, 2025 File No. 001-39186 Dear Latha Vairavan: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
December 2, 2025
Latha Vairavan
Chief Financial Officer
Arcutis Biotherapeutics, Inc.
3027 Townsgate Road Suite 300
Westlake Village, California 91361
Re:Arcutis Biotherapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2024
Filed February 25, 2025
File No. 001-39186
Dear Latha Vairavan:
We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences